U.S. Health Care REITs Stock News

Serve Robotics (SERV) has caught investor attention after reporting a very large jump in first quarter 2026 fleet services revenue, expanding into 44 cities via the Diligent Robotics acquisition, and launching a NoScrubs autonomous laundry delivery pilot. See our latest analysis for Serve Robotics. Despite the fresh interest around the Diligent Robotics deal and the NoScrubs pilot, the stock’s recent momentum has been weak, with the 30 day share price return down 15.07% and the year to date...

In early June 2026, Honeywell International reaffirmed its full-year 2026 guidance, outlining expected sales of US$38.8 billion to US$39.8 billion and sharing a preliminary outlook for the post-spin Honeywell Technologies business ahead of the June 29 spin-off of Honeywell Aerospace. At the same time, Honeywell added experienced industrial executive Jillian Evanko to its board and retained significant voting power in newly listed quantum venture Quantinuum, underscoring how the group is...

If you are wondering whether Target's current share price lines up with what the company might be worth, this article breaks down the valuation so you can see how the numbers compare. After closing at US$132.64, the stock has returned 7.1% over the past week, 8.9% over the past month and 32.0% year to date, with a 39.4% return over the past year but a 33.2% decline over five years. Recent price moves sit against a backdrop of ongoing attention on large US retailers. Investors are weighing...

Everspin Technologies (MRAM) has drawn fresh attention after recent trading left the stock up 5.9% on the day, but down 14.8% over the past week and 45.0% over the past month. See our latest analysis for Everspin Technologies. That sharp 30 day share price decline of 45.0% comes after a very strong run, with the 90 day share price return at 174.38% and the 1 year total shareholder return at 296.72%. Recent momentum therefore appears to be cooling following a powerful move. If Everspin’s...

In early June 2026, rumors surfaced that Yatra’s founders were exploring a sale of a controlling stake and had approached several potential buyers, while MakeMyTrip declined to comment beyond reiterating its focus on inorganic growth in travel-adjacent categories. At the same time, options data and analyst revisions pointed to rising pessimism around MakeMyTrip’s upcoming earnings, with expectations of weaker profitability despite modest revenue growth. We’ll now examine how this combination...

Earlier in 2026, Frontline announced roughly a 50% dividend increase after reporting its strongest quarterly adjusted profit since 2004, helped by disrupted crude shipping routes following the effective closure of the Strait of Hormuz during the Iran conflict. This combination of record profitability and a sharply higher, but inherently variable, payout highlights how sensitive Frontline’s income profile is to sudden shifts in global trade flows. We’ll now explore how this profit-fueled...

If you are wondering whether CME Group at around US$262 per share reflects fair value or an opportunity, this article breaks down what the current price might be implying about the stock. The stock is up 2.4% over the last week, even though it is down 8.2% over the past month, 2.8% year to date, and has returned 0.5% over the last year. Longer term returns of 63.6% over three years and 49.1% over five years provide additional context. Recent headlines around CME Group have continued to focus...

Ford Motor (NYSE:F) is ramping up F Series truck production after supply disruptions from major fires at primary aluminum supplier Novelis. Novelis has restarted its hot mill operations, restoring a key aluminum source for Ford's truck manufacturing. The earlier outages contributed to a significant shortfall in planned F Series output for 2025, which Ford now aims to recover. The production catch up plan is expected to influence revenues, dealer lot availability, and share in the full size...

This article examines whether General Dynamics at US$358.86 is priced for perfection or still offers value, focusing on what the current share price implies. The stock has returned 5.1% over the past week, 3.6% over the past month, 4.5% year to date and 30.6% over the past year, with longer term returns of 77.5% over three years and 112.8% over five years shaping how investors think about risk and reward. Recent news coverage has focused on General Dynamics' position as a major US defense...

Wondering if Electronic Arts at around US$203 per share still offers fair value, or if the recent run has pushed the stock too far. The stock is roughly flat over the past week, up 1.4% over the last month, slightly down 0.7% year to date, yet has delivered 35.9% over 1 year, 59.8% over 3 years and 46.9% over 5 years, which can change how you think about risk and return. Recent coverage has focused on Electronic Arts as a large US gaming company, including ongoing attention on its content...

Harrow (HROW) put vernal keratoconjunctivitis back in focus with the relaunch of VERKAZIA, a steroid sparing calcineurin inhibitor eye drop, backed by an access centric commercial push. See our latest analysis for Harrow. The VERKAZIA relaunch has come alongside a sharp improvement in recent share price momentum, with a 1 month share price return of 29.69% and a 3 month share price return of 10.41%. This is despite the year to date share price return being down 24.56% and the 5 year total...

NVR (NVR) shares came under pressure after the company reported quarterly revenue down 21.7% year on year, missing analysts' expectations by 7.8%. Adjusted operating income also fell short, and investors responded by selling. See our latest analysis for NVR. Despite the post earnings setback, NVR's recent 1 month share price return of 11.8% contrasts with a year to date share price decline of 11%. The 5 year total shareholder return of 37.9% points to steadier long term compounding and...

Wondering whether Ategrity Specialty Insurance Company Holdings at US$21.02 is pricing in its potential, or leaving room on the table for value focused investors. The stock has moved 8.1% over the past week and 8.4% over the past month, while being down 12.4% over the last year, which may have shifted how investors view both its upside and its risks. Recent headlines have focused on Ategrity Specialty Insurance Company Holdings as part of broader interest in specialty insurers, with...

LendingClub’s recent annual meeting approved another amendment to its Certificate of Incorporation, while Q1 2026 results showed higher earnings, stronger loan originations, and better credit performance alongside plans to expand into home improvement financing and rebrand as Happen Bank. This combination of operational momentum, tighter credit outcomes, and a shift toward broader consumer finance offerings marks a meaningful evolution in LendingClub’s business profile. We’ll now examine how...

Relay Therapeutics recently gained shareholder approval at its June 9, 2026 annual meeting to amend its certificate of incorporation and raise its authorized common stock capacity from 300,000,000 to 450,000,000 shares. At the same time, research firms highlighted encouraging initial clinical data for zovegalisib in vascular malformations, prompting more optimistic assessments of the drug’s commercial potential. We’ll now examine how the upgraded outlook for zovegalisib’s commercial...

Trane Technologies (NYSE:TT) has appointed Donald E. Simmons as Chief Operating Officer. Simmons has been with the company for 25 years and has held leadership roles across multiple business units. As COO, he will oversee all regional business units and operations with a focus on tighter operational alignment. The appointment is positioned as an important step in advancing the company’s growth strategy. Trane Technologies, traded on the NYSE under the ticker TT, focuses on heating,...

Tripadvisor (NasdaqGS:TRIP) has released its 2026 Travelers' Choice Best of the Best Hotels awards. The rankings highlight hotels in the US, Vietnam, Indonesia, and Ireland based on traveler reviews and experiences. The awards spotlight emerging travel trends and global hospitality quality across several key destinations. Tripadvisor, through its core reviews and travel guidance platform, plays a central role in how travelers research and select hotels worldwide. The 2026 Travelers' Choice...

Investors may wish to note that the Director of Silvaco Group, Inc. , Iliya Pesic, recently netted US$78k from selling...

Shoe Carnival, Inc.'s ( NASDAQ:SCVL ) recent soft profit numbers didn't appear to worry shareholders, as the stock...

Viking Therapeutics (NasdaqCM:VKTX) has appointed Dr. Hubert C. Chen as chief medical officer. Dr. Chen brings extensive experience in drug discovery, clinical development, and regulatory strategy. The appointment expands the company’s senior leadership as its pipeline of metabolic and endocrine therapies progresses. Viking Therapeutics focuses on developing therapies for metabolic and endocrine disorders, areas that continue to attract attention as obesity, liver disease, and related...

Dana stock performance snapshot Dana (DAN) has drawn investor attention after recent trading, with the stock down 15% over the past day and 18% over the past week, extending a month decline of 11%. See our latest analysis for Dana. That sharp 15.1% one day share price decline adds to weaker recent momentum, even though year to date the share price return remains positive and the 1 year total shareholder return of 76.3% is much stronger. If recent volatility has you reassessing opportunities...

Earlier this week, nCino reported Q1 revenue of US$159.4 million, up 10.6% year on year and ahead of analyst expectations, alongside beats on billings and EBITDA. Management also emphasized growing customer validation of its AI product strategy and increased investment in the platform, underlining how AI is becoming central to nCino’s value proposition. Next, we’ll explore how this stronger-than-expected quarter and progress on AI integration may influence nCino’s broader investment...

In June 2026, Organon reported that the US FDA approved a supplemental Biologics License Application expanding TOFIDENCE, a tocilizumab biosimilar to ACTEMRA, to treat CAR T cell-induced severe cytokine release syndrome and certain hospitalized COVID-19 patients aged 2 years and older. This makes TOFIDENCE the first tocilizumab biosimilar available in the US across a broad range of autoimmune and acute inflammatory indications, potentially reinforcing Organon’s focus on expanding its...

Wondering if Goldman Sachs Group at US$1,035.64 is still offering value after a strong run, or if most of the opportunity is already priced in. The stock is down 5.2% over the past week, up 9.5% over the past month, up 13.3% year to date and up 69.0% over the past year. This naturally raises questions about both growth potential and changing risk perceptions. Recent coverage has focused on how a long stretch of strong returns, including a gain of very large magnitude over three years and...